WAT 357.77 (+3.79%)
US9418481035Medical Diagnostics & ResearchDiagnostics & Research

Waters (WAT) Competitor Comparison

We are evaluating the key criteria listed to compare Waters (WAT) against its competitors in the Diagnostics & Research industry.

Total Cash - WAT ranking 19 / 57

These are the competitors of Waters in the industry Diagnostics & Research ranked by total cash
1. Danaher DHR
12.28B
2. Thermo Fisher Scientific TMO
6.15B
3. DexCom DXCM
3.24B
4. Agilent Technologies A
1.59B
5. IQVIA Holdings IQV
1.33B
6. Guardant Health GH
1.15B
7. Qiagen QGEN
1.02B
8. Natera NTRA
936.56M
9. Illumina ILMN
933M
10. Global Cord Blood CO
926.78M
11. Pacific Biosciences of California PACB
767.79M
12. Exact Sciences EXAS
734.41M
13. Laboratory Corp of America Holdings LH
727.9M
14. Lantheus Holdings LNTH
614.13M
15. Fulgent Genetics FLGT
467.8M
16. PerkinElmer PKI
454.36M
17. NeoGenomics NEO
402.26M
18. RadNet RDNT
337.88M
19. Waters WAT
337.31M
20. Twist Bioscience TWST
336.41M
21. IDEXX Laboratories IDXX
331.7M
22. Icon ICLR
315.02M
23. Ortho Clinical Diagnostics Holdings OCDX
281.1M
24. CareDx CDNA
268.18M
25. Sotera Health SHC
245.37M
26. Neogen NEOG
230.27M
27. MaxCyte MXCT
190.24M
28. Charles River Laboratories CRL
157.17M
29. Quest Diagnostics DGX
143M
30. Olink Holding OLK
130.28M
31. Heska HSKA
125.21M
32. Personalis PSNL
120.66M
33. Medpace Holdings MEDP
95.21M
34. Syneos Health SYNH
91.17M
35. Prenetics Global PRE
88.99M
36. Myriad Genetics MYGN
86.3M
37. Mettler-Toledo MTD
69.68M
38. Enzo Biochem ENZ
69.21M
39. Co-Diagnostics CODX
63.43M
40. Sera Prognostics SERA
46.12M
41. DarioHealth DRIO
43.88M
42. Neuronetics STIM
35.85M
43. Inotiv NOTV
35.49M
44. MDxHealth MDXH
32.71M
45. Exagen XGN
28.45M
46. Bioventus BVS
26.83M
47. Anixa Biosciences ANIX
25.53M
48. Biodesix BDSX
19.84M
49. Trinity Biotech TRIB
14.23M
50. Organovo Holdings ONVO
7.62M
51. Aspira Womens Health AWH
5.1M
52. Interpace Biosciences IDXG
5.03M
53. SeqLL SQL
4.79M
54. bioAffinity Technologies BIAF
4.51M
55. National Research NRC
3.83M
56. Precipio PRPO
1.56M
57. Psychemedics PMD
1.37M

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.